Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

被引:42
作者
GrondahlHansen, J
Hilsenbeck, SG
Christensen, IJ
Clark, GM
Osborne, CK
Brunner, N
机构
[1] RIGSHOSP,FINSEN LAB,DK-2100 COPENHAGEN,DENMARK
[2] UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ONCOL,SAN ANTONIO,TX 78284
关键词
breast cancer; uPA; PAI-1; prognosis;
D O I
10.1023/A:1005744914124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer cell invasion is accomplished by the concerted action of several extracellular proteolytic enzyme systems, one of which is the urokinase plasminogen activation system. The different components of this system, e.g. urokinase plasminogen activator (uPA), its receptor uPAR, as well as its main inhibitor plasminogen activator inhibitor type 1 (PAI-1) have all been shown to have prognostic value in breast cancer, i.e. high tumor levels are associated with a poor prognosis. In order to further substantiate the prognostic value of uPA and PAI-1, we have tested the cutpoints (median values and optimized cutpoints) from our first study (Cancer Res 53: 2513-2521, 1993) in an independent group of breast cancer patients. Breast cancer cytosols from 100 premenopausal and 150 post-menopausal node positive patients were included. The median observation time was 80 months (range 49-145). Univariate analysis showed that high PAI-1 levels (above the median PAI-1 value) were significantly associated with short recurrence-free survival (RR: 1.65; 95% CI: 1.04-2.63; P = 0.03) and short overall survival (RR: 2.46; 95% CI: 1.52-3.96; P = 0.0001) in postmenopausal patients. Postmenopausal patients with high uPA levels (above the median uPA value) had a significantly shorter recurrence-free survival (RR: 2.04; 95% CI: 1.17-3.56; P = 0.01) and overall survival (RR: 2.07; 95% CI: 1.16-3.70; P = 0.01) than patients with low uPA values. Nearly identical results were obtained when using the optimized PAI-1 or uPA value. In a Cox multivariate analysis which included other established prognostic factors, high PAI-1 was found to be an independent prognostic variable predicting short overall survival with a relative risk of 2.27 in postmenopausal women, and high uPA was found to be an independent prognostic variable predicting short recurrence-free survival with a relative risk of 1.86 in postmenopausal women. The present study indicates that uPA and PAI-1 are independent and significant prognostic variables in subsets of breast cancer patients.
引用
收藏
页码:153 / 163
页数:11
相关论文
共 43 条
[21]  
HOLLAS W, 1991, CANCER RES, V51, P3690
[22]  
JANICKE F, 1994, CANCER RES, V54, P2527
[23]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) ANTIGEN IS A PREDICTOR OF EARLY RELAPSE IN BREAST-CANCER [J].
JANICKE, F ;
SCHMITT, M ;
HAFTER, R ;
HOLLRIEDER, A ;
BABIC, R ;
ULM, K ;
GOSSNER, W ;
GRAEFF, H .
FIBRINOLYSIS, 1990, 4 (02) :69-78
[24]   CLINICAL RELEVANCE OF THE UROKINASE-TYPE AND TISSUE-TYPE PLASMINOGEN ACTIVATORS AND OF THEIR TYPE-1 INHIBITOR IN BREAST-CANCER [J].
JANICKE, F ;
SCHMITT, M ;
GRAEFF, H .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1991, 17 (03) :303-312
[25]  
KOBAYASHI H, 1992, CANCER RES, V52, P3610
[26]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[27]  
MACKINNON WB, 1992, INVAS METAST, V12, P241
[28]   TUMOR INVASION THROUGH THE HUMAN AMNIOTIC MEMBRANE - REQUIREMENT FOR A PROTEINASE CASCADE [J].
MIGNATTI, P ;
ROBBINS, E ;
RIFKIN, DB .
CELL, 1986, 47 (04) :487-498
[29]  
Nielsen BS, 1996, LAB INVEST, V74, P168
[30]   PURIFICATION OF ZYMOGEN TO PLASMINOGEN-ACTIVATOR FROM HUMAN GLIOBLASTOMA CELLS BY AFFINITY-CHROMATOGRAPHY WITH MONOCLONAL-ANTIBODY [J].
NIELSEN, LS ;
HANSEN, JG ;
SKRIVER, L ;
WILSON, EL ;
KALTOFT, K ;
ZEUTHEN, J ;
DANO, K .
BIOCHEMISTRY, 1982, 21 (25) :6410-6415